“Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?”. Cardiovasc Drugs Ther19 (5): 311-313. (2005). doi:10.1007/s10557-005-4971-1. PMID16382292.
“Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite?”. Clin Investig71 (3): 240-246. (2007). PMID8481628.
“Severe allopurinol toxicity; Description and guidelines for prevention in patients with renal insufficiency”. Am J Med76 (1): 47-56. (1984). PMID6691361.
“Allopurinol and oxypurinol in human breast milk”. Clin Investig71 (2): 161-164. (1993). PMID8461629.
“Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?”. Cardiovasc Drugs Ther19 (5): 311-313. (2005). doi:10.1007/s10557-005-4971-1. PMID16382292.